Get the Stockscreener App
3.71
4.21%
0.15
After Hours:
3.75
0.04
+1.08%
Omniab Inc stock is traded at $3.71, with a volume of 695.66K.
It is up +4.21% in the last 24 hours and up +0.00% over the past month.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
See More
Previous Close:
$3.56
Open:
$3.55
24h Volume:
695.66K
Relative Volume:
1.40
Market Cap:
$448.96M
Revenue:
$34.16M
Net Income/Loss:
$-50.62M
P/E Ratio:
-7.3031
EPS:
-0.508
Net Cash Flow:
$703.00K
1W Performance:
+15.58%
1M Performance:
+0.00%
6M Performance:
-10.17%
1Y Performance:
-33.03%
1-Day Range:
$3.50
$3.715
1-Week Range:
$3.12
$3.715
52-Week Range:
$3.1002
$6.5488
Omniab Inc Stock (OABI) Company Profile
Name
Omniab Inc
Sector
Industry
Phone
510-250-7800
Address
5980 HORTON STREET, EMERYVILLE
Compare OABI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
3.71 | 448.96M | 34.16M | -50.62M | 703.00K | -0.508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
Omniab Inc Stock (OABI) Latest News
OABI Shares Experience Surge in Value - Knox Daily
OmniAb to Participate in Two Investor Conferences in March -February 03, 2025 at 04:58 pm EST - Marketscreener.com
Major Healthcare Conference Double-Header: OmniAb Sets Stage for Strategic Investor Presentations - StockTitan
OmniAb, Inc. (NASDAQ:OABI) Shares Sold by Chicago Capital LLC - MarketBeat
Court Place Advisors LLC Sells 77,445 Shares of OmniAb, Inc. (NASDAQ:OABI) - MarketBeat
Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm - The Malaysian Reserve
JPMorgan Chase & Co. Sells 16,670 Shares of OmniAb, Inc. (NASDAQ:OABI) - Defense World
3 US Penny Stocks With Market Caps Over $300M To Watch - Yahoo Finance
OmniAb Insider Ups Holding During Year - Yahoo Finance
Have OmniAb Insiders Been Selling Stock? - Simply Wall St
Insider Selling: OmniAb, Inc. (NASDAQ:OABI) CEO Sells 41,811 Shares of Stock - MarketBeat
Insider Selling: OmniAb, Inc. (NASDAQ:OABI) Insider Sells 25,489 Shares of Stock - MarketBeat
Omniab chief legal officer Charles Berkman sells shares worth $82,584 By Investing.com - Investing.com Australia
Omniab CEO Matthew Foehr sells $135,467 in stock By Investing.com - Investing.com Australia
OmniAb, Inc. (NASDAQ:OABI) CFO Sells 15,526 Shares - MarketBeat
Omniab CEO Matthew Foehr sells $135,467 in stock - Investing.com India
Omniab CFO Kurt Gustafson sells shares worth $50,304 By Investing.com - Investing.com South Africa
Omniab chief legal officer Charles Berkman sells shares worth $82,584 - Investing.com
Omniab CFO Kurt Gustafson sells shares worth $50,304 - Investing.com
OmniAb, Inc. (NASDAQ:OABI) Shares Acquired by Barclays PLC - MarketBeat
OmniAb, Inc. (NASDAQ:OABI) Shares Bought by Barclays PLC - Defense World
OmniAb (NASDAQ:OABI) Hits New 52-Week Low – Here’s What Happened - Defense World
OABI stock touches 52-week low at $3.43 amid market challenges - Investing.com Nigeria
OmniAb (NASDAQ:OABI) Hits New 1-Year LowTime to Sell? - MarketBeat
OmniAb Announces Publication of Scientific Paper on Heavy Chain- - GuruFocus.com
FY2024 EPS Estimates for OmniAb Raised by Leerink Partnrs - Defense World
FY2024 EPS Estimates for OmniAb Lifted by Leerink Partnrs - MarketBeat
OmniAb Presents High-Throughput Single B-cell Screening xPlorati - GuruFocus.com
OmniAb, Inc. (NASDAQ:OABI) Shares Sold by Jane Street Group LLC - Defense World
Geode Capital Management LLC Lowers Position in OmniAb, Inc. (NASDAQ:OABI) - Defense World
Barclays PLC Increases Stock Holdings in OmniAb, Inc. (NASDAQ:OABI) - Defense World
Why OmniAb, Inc. (OABI) Is One of the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey
US Penny Stocks To Watch In December 2024 - Simply Wall St
OmniAb (NASDAQ:OABI) Stock Price Up 2.8% – Still a Buy? - Defense World
State Street Corp Grows Holdings in OmniAb, Inc. (NASDAQ:OABI) - Defense World
OmniAb (NASDAQ:OABI) Shares Up 2.8%Here's What Happened - MarketBeat
With 55% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns - Yahoo Finance
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $542,000 Stock Holdings in OmniAb, Inc. (NASDAQ:OABI) - Defense World
Fmr LLC Acquires 13,324 Shares of OmniAb, Inc. (NASDAQ:OABI) - Defense World
First Trust Water ETF (NYSEARCA:FIW) Shares Acquired by Fmr LLC - Defense World
OABI stock touches 52-week low at $3.55 amid market challenges - Investing.com
OmniAb Unveils Revolutionary AI-Powered Antibody Discovery Platform, Launches Advanced OmniHub™ Portal - StockTitan
Tharimmune Advances TH104 Clinical Program: Phase 2 Trial Set for 2025 After Positive Phase 1 Results - StockTitan
OmniAb's SWOT analysis: antibody discovery firm's stock poised for growth By Investing.com - Investing.com South Africa
OmniAb's SWOT analysis: antibody discovery firm's stock poised for growth - Investing.com India
Charles Schwab Investment Management Inc. Increases Holdings in OmniAb, Inc. (NASDAQ:OABI) - Defense World
Omniab Inc Stock (OABI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):